Form 4: Perrigo CEO Patrick Lockwood-Taylor Reports Significant Restricted Stock Unit Grant

Sentiment:

Insider Transaction Report


Perrigo Company plc's CEO and Director, Patrick Lockwood-Taylor, reported the acquisition of 75,688 Restricted Stock Units, vesting over three years, as part of his compensation.

Summary

  • Patrick Lockwood-Taylor, the Chief Executive Officer and a Director of Perrigo Company plc (PRGO), filed a Form 4 disclosing changes in his beneficial ownership.
  • On June 6, 2025, Mr. Lockwood-Taylor acquired 75,688 Restricted Stock Units (RSUs).
  • Each RSU represents a contingent right to receive one Perrigo Company plc ordinary share.
  • These RSUs are scheduled to vest in three equal annual installments, with the first installment beginning on June 6, 2026.
  • Following this reported transaction, Mr. Lockwood-Taylor directly beneficially owns 67,260 ordinary shares and 75,688 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The document reports a routine executive compensation grant, which is a positive for aligning management incentives with shareholder interests, but does not contain new operational or financial performance data that would significantly alter investment sentiment.

Positives

  • The grant of Restricted Stock Units to the CEO aligns management's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.

Future Outlook

The vesting schedule for the Restricted Stock Units indicates a long-term incentive structure for the CEO, aligning his future compensation with the company's performance over the next three years.

Industry Context

The grant of Restricted Stock Units is a common and standard practice for executive compensation across various industries, designed to incentivize long-term performance and align management interests with shareholder value.

Comparison to Industry Standards

  • The use of Restricted Stock Units (RSUs) as a form of executive compensation is a widely adopted practice across publicly traded companies, including those in the pharmaceutical and consumer healthcare sectors.
  • The multi-year vesting schedule (three equal annual installments) is typical for such grants, aiming to retain executives and ensure sustained performance alignment, comparable to practices at companies like Johnson & Johnson or Procter & Gamble for their senior leadership.

Related Party Transactions

  • Grant of 75,688 Restricted Stock Units to Patrick Lockwood-Taylor, the CEO and a Director of Perrigo Company plc, as part of his compensation package.

Stakeholder Impact

  • Shareholders: The RSU grant aligns the CEO's financial incentives with the long-term performance of the company's stock, potentially benefiting shareholders through improved management focus on value creation.
  • Management (CEO): Patrick Lockwood-Taylor receives equity-based compensation, which forms a significant part of his overall remuneration and ties his personal wealth to the company's success.

Next Steps

  • The Restricted Stock Units will begin vesting in three equal annual installments starting on June 6, 2026.

Key Dates

DateDescription
06/06/2025Date of earliest transaction, specifically the acquisition of 75,688 Restricted Stock Units.
06/10/2025Date the Form 4 was signed by the attorney-in-fact for Mr. Patrick Lockwood-Taylor.
06/06/2026Start date for the first of three equal annual vesting installments for the acquired Restricted Stock Units.

Keywords

Perrigo, PRGO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Patrick Lockwood-Taylor, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.